Ataxia Treatment Sector: Growth Drivers and Challenges
Growth Drivers
- Efforts to increase access to advanced care: As a strategy to combat payers' pricing pressure, Individual government and non-profit organizations are engaging their resources to enhance accessibility in the ataxia treatment market. This can be testified by the 12.3% increase in fund allocation in this category by the public health system in Germany, during the period from 2020 to 2024. Further, the Federal Ministry of Health of the country calculated the net allocation in 2024 to be USD 546.3 million. This signifies the substantial capital influx from the dedicated authorities, creating new business opportunities for this merchandise.
- Pharmaceutical and biotech R&D investments: The growth momentum in the ataxia treatment market is also followed by participation and engagement in extensive research and development cohorts. For instance, the NIH allocated USD 320.1 million in funds to accelerate R&D in this category in 2024. This helps the sector garner new possibilities and fields of application, inspiring more companies to be involved in this cohort of innovation. Following the same pathway, in 2024, Biogen collaborated with the NIH to advance CRISPR-based treatments targeting ataxia, aiming to launch newly developed products by 2027. Moreover, the recent clinical findings are empowering the evolution of this sector.
Challenges
- Infrastructural limitations and resistance: The absence of adequate diagnostic facilities, particularly in underserved regions, is the major hurdle in widespread adoption in the ataxia treatment market. In this regard, in 2023, the ICMR reported that 40.2% of the related incidences in India were undiagnosed on account of limited access and awareness of genetic testing. This requires heavy healthcare infrastructure investments and development to broaden the consumer base in rural areas. Following the same pathway, in 2024, Novartis funded over 10 specialized neurology clinics in rural areas of India, which further escalated the detection rate by 25.3%. As a result, the importance of large-scale upgradation pushed local authorities to invest more in this field.
Ataxia Treatment Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
7% |
|
Base Year Market Size (2024) |
USD 850.4 million |
|
Forecast Year Market Size (2037) |
USD 2.7 billion |
|
Regional Scope |
|
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2024, the industry size of the ataxia treatment market was over USD 850.4 million.
The market size for the ataxia treatment market is projected to reach USD 2.7 billion by the end of 2037 expanding at a CAGR of 7% during the forecast period i.e., between 2025-2037.
The major players in the market are Biogen, Novartis, Roche, Pfizer, Ionis Pharmaceuticals, and others.
In terms of treatment, the hospitals segment is anticipated to garner the largest market share of 45.2% by 2037 and display lucrative growth opportunities during 2025-2037.
The market in North America is projected to hold the largest market share of 42.5% by the end of 2037.